- 2025-05-16
- Frontiers in medicine 12
- Alireza Khiabani
- Roohollah Mirzaee Khalilabadi
- Hajar Mardani Valandani
- Zahra Khoshnegah
- Alireza Khanahmad
- Hojat Shahraki
- Najmeh Nezamabadipour
- Alireza Farsinejad
- Mehran Rahimlou
Study Design
- Type
- Systematic Review
- Population
- patients with immune thrombocytopenia (ITP)
- Methods
- systematic review with comprehensive search in five databases from 1980 to July 2024, adhering to PRISMA 2020 guidelines
Background
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production. Recent evidence suggests a role for gut microbiome dysbiosis in autoimmune diseases, but its association with ITP remains unclear. This systematic review explores the potential link between the gut microbiome and ITP pathophysiology.Methods
We conducted a comprehensive search in five databases (MEDLINE, Scopus, Web of Science, Cochrane Library, Embase) from 1980 to July 2024, adhering to PRISMA 2020 guidelines. Studies assessing the gut microbiome in patients with ITP were included. The primary outcome was alterations in gut microbiota composition, and study selection was performed in three phases, with discrepancies resolved through consensus.Results
From 480 studies screened, 12 met the inclusion criteria. The studies revealed significant alterations in gut microbiota composition, particularly at the phylum level. An increase in Bacteroidetes and Proteobacteria was observed in some studies, while others reported a decrease in these phyla. Firmicutes showed inconsistent results across studies. Alpha and beta diversity analysis also yielded conflicting results, with some studies reporting decreased diversity, while others found no significant difference or an increase.Conclusion
The results suggest a potential link between gut microbiota dysbiosis and ITP, though findings remain inconsistent across studies. Further well-designed research is needed to clarify the role of the microbiome in ITP, with implications for novel therapeutic approaches.